

General information about company	
Scrip code*	524703
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE751D01014
Name of company	SANDU PHARMACEUTICALS LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	05-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	27-04-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Manufacture and Marketing of Ayurvedic Medicine
Start date and time of board meeting	05-05-2026 15:00
End date and time of board meeting	05-05-2026 17:50
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	13-02-2025
Indicate Company website link for updated RPT policy of the Company	https://sandu.in/wp-content/uploads/2025/04/policy-on-materiality-and-dealing-with-Related-Party-Transaction-13.02.2025-1.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes
No. of times funds raised during the quarter	3
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No The Company has not made any default on loans and debt securities for the Q ended and year ended 31.03.2026

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-01-2026	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	1685.34	6993.45
	Other income	36.51	44.44
	Total income	1721.85	7037.89
2	Expenses		
(a)	Cost of materials consumed	383.94	1101.18
(b)	Purchases of stock-in-trade	351.54	1648.07
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-83.01	407.95
(d)	Employee benefit expense	274.28	1069.08
(e)	Finance costs	2.56	11.21
(f)	Depreciation, depletion and amortisation expense	16.49	67.7
(g)	Other Expenses		
1	Other Expenses	701.34	2467.16
	Total other expenses	701.34	2467.16
	Total expenses	1647.14	6772.35
3	Total profit before exceptional items and tax	74.71	265.54
4	Exceptional items	0	0
5	Total profit before tax	74.71	265.54
6	Tax expense		
7	Current tax	54.01	78.52
8	Deferred tax	16.36	10.41
9	Total tax expenses	70.37	88.93
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	4.34	176.61
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	4.34	176.61
17	<u>Other comprehensive income net of taxes</u>	66.34	66.34
18	Total Comprehensive Income for the period	70.68	242.95
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	Details of equity share capital		

	Paid-up equity share capital	966.1	966.1	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve		0	
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	0.04	1.83	
	Diluted earnings (loss) per share from continuing operations	0.04	1.83	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	0.04	1.83	
	Diluted earnings (loss) per share from continuing and discontinued operations	0.04	1.83	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Text Block

Textual Information(4)

1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 .The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.

2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.

3. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 05/05/2026.

4. The Figures for the quarter ended 31 st March, 2026 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.

5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.

For Sandu Pharmaceuticals Ltd

Date: - 05/05/2026 Umesh Sandu
Managing Director
DIN no: - 01132141

Statement of Asset and Liabilities		
	Particulars	Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	868.47
	Capital work-in-progress	6.41
	Investment property	
	Goodwill	942.13
	Other intangible assets	1.86
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	Non-current financial assets	
	Non-current investments	1229.8
	Trade receivables, non-current	
	Loans, non-current	3.08
	Other non-current financial assets	
1		
2		
3		
4		
5		
	Details of other non-current financial assets	
	Total of other non-current financial assets	
	Total non-current financial assets	1232.88
	Deferred tax assets (net)	
	Other non-current assets	
1	Other Non-Current Assets	3.24
2		
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	3.24
	Total non-current assets	3054.99
2	Current assets	
	Inventories	1047.13
	Current financial asset	
	Current investments	0
	Trade receivables, current	541.09
	Cash and cash equivalents	590.77
	Bank balance other than cash and cash equivalents	94.82
	Loans, current	0
	Other current financial assets	
1		

2		
3		
4		
5		
	Details of other current financial assets	
	Total of Other current financial assets	
	Total current financial assets	1226.68
	Current tax assets (net)	
	Other current assets	
1	Other Current Assets	258.13
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	258.13
	Total current assets	2531.94
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	5586.93
	Equity and liabilities	
1	Equity	
	Equity attributable to owners of parent	
	Equity share capital	966.1
	Other equity	3401.23
	Total equity attributable to owners of parent	4367.33
	Non controlling interest	
	Total equity	4367.33
2	Liabilities	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	30.95
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
	Total Trade payable	
	Other non-current financial liabilities	
1		
2		
3		
4		
5		
	Details of other non-current financial liabilities	
	Total of other non-current financial liabilities	
	Total non-current financial liabilities	30.95
	Provisions, non-current	0
	Deferred tax liabilities (net)	146.44
	Deferred government grants, Non-current	
	Other non-current liabilities	
1		
2		
3		

4		
5		
	Details of other non-current liabilities	
	Total of other non-current liabilities	
	Total non-current liabilities	177.39
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	10.98
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	61.72
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	385.03
	Total Trade payable	446.75
	Other current financial liabilities	
1	Other Financial Liabilities	31.27
2		
3		
4		
5		
	Details of other current financial liabilities	
	Total of other current financial liabilities	31.27
	Total current financial liabilities	489
	Other current liabilities	
1	Other Current Liabilities	206.58
2		
3		
4		
5		
	Details of other current liabilities	
	Total of other current liabilities	206.58
	Provisions, current	346.63
	Current tax liabilities (Net)	
	Deferred government grants, Current	
	Total current liabilities	1042.21
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	1219.6
	Total equity and liabilities	5586.93
	Disclosure of notes on assets and liabilities	

Other Comprehensive Income				
		Date of start of reporting period	01-01-2026	01-04-2025
		Date of end of reporting period	31-03-2026	31-03-2026
		Whether results are audited or unaudited	Audited	Audited
		Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]			
1	Amount of items that will not be reclassified to profit and loss			
1	Remeasurement gains/(losses) on post employment defined benefit plans	8.11		8.11
2	Fair value changes of investments	74.61		74.61
3	Income tax relating to items that will not be reclassified to profit or loss	-16.38		-16.38
	Total Amount of items that will not be reclassified to profit and loss	66.34		66.34
2	Income tax relating to items that will not be reclassified to profit or loss	0.00		0.00
3	Amount of items that will be reclassified to profit and loss			
	Total Amount of items that will be reclassified to profit and loss			
4	Income tax relating to items that will be reclassified to profit or loss			
5	Total Other comprehensive income	66.34		66.34

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	265.54
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	11.21
	Adjustments for decrease (increase) in inventories	367.73
	Adjustments for decrease (increase) in trade receivables, current	-113.96
	Adjustments for decrease (increase) in trade receivables, non-current	48.6
	Adjustments for decrease (increase) in other current assets	25.71
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	-2.03
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	0
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	67.7
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	13.84
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	5.89
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	8.11
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	421.02
	Net cash flows from (used in) operations	686.56
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	74.98
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	611.58
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0

	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	72
	Proceeds from sales of investment property	70
	Purchase of investment property	28
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	74.61
	Purchase of other long-term assets	107.38
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	5.89
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) investing activities	-56.88
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	0
	Payments of lease liabilities	5.82
	Dividends paid	77.29
	Interest paid	11.21
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	-94.32
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	460.38
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	460.38

	Cash and cash equivalents cash flow statement at beginning of period	130.39
	Cash and cash equivalents cash flow statement at end of period	590.77

Format for Disclosure of Related Party Transactions (applicable only for half

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary							
1	Sandu Pharmaceuticals Limited	AAACS6291G	Sandu Brothers Pvt. Ltd.	AADCS9226L	Entities in which KMP are interested	Any other transaction	Balance Payable	10000	Approved by Board of directors and shareholders			45.17
2	Sandu Pharmaceuticals Limited	AAACS6291G	Sandu Brothers Pvt. Ltd.	AADCS9226L	Entities in which KMP are interested	Sale of goods or services		10000	Approved by Board of directors and shareholders			18.11
3	Sandu Pharmaceuticals Limited	AAACS6291G	Sandu Brothers Pvt. Ltd.	AADCS9226L	Entities in which KMP are interested	Purchase of goods or services		10000	Approved by Board of directors and shareholders			-351.5
4	Sandu Pharmaceuticals Limited	AAACS6291G	Sandu Brothers Pvt. Ltd.	AADCS9226L	Entities in which KMP are interested	Any other transaction	Royalty paid	10000	Approved by Board of directors and shareholders			-32.9:
5	Sandu Pharmaceuticals Limited	AAACS6291G	Shri. Umesh B. Sandu	ABWPS9336G	Key Managerial Person	Remuneration			Approved by Board of directors and shareholders			-28.9:
6	Sandu Pharmaceuticals Limited	AAACS6291G	Shri Vijay Kajarekar	ADXPk1740P	Key Managerial Person	Remuneration			As per the terms of employment contract			-1.55
7	Sandu Pharmaceuticals Limited	AAACS6291G	Smt. Pratika Mhambray	CTQPS2943K	Key Managerial Person	Remuneration			As per the terms of employment contract			-2.06
Total value of transaction during the reporting period												-353.7

Details of Impact of Audit Qualification

Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	M/S Dileep and Prithvi	Yes	31-10-2026

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	31-03-2021
Amount Raised	263.8
Report filed for Quarter ended	31-03-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	NOT APPLICABLE
Comments of the Audit Committee after review	Audit Committee after review of the statement has noted and approved the same
Comments of the auditors, if any	

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company	NA	263.8	0	263.8	0	

Signatory Details

Name of signatory	UMESH SANDU
Designation of person	Managing Director
Place	MUMBAI
Date	05-05-2026

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	28-02-2022
Amount Raised	138.05
Report filed for Quarter ended	31-03-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	NOTAPPLICABLE
Comments of the Audit Committee after review	Audit Committee after review of the statement has noted and approved the same
Comments of the auditors, if any	

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company	NA	138.05	0	138.05	0	

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (3)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	14-07-2022
Amount Raised	131.95
Report filed for Quarter ended	31-03-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	NOTAPPLICABLE
Comments of the Audit Committee after review	Audit Committee after review of the statement has noted and approved the same
Comments of the auditors, if any	

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company	NA	131.95	0	43.36	0	

